O	0	10	Inhibition
O	11	13	of
O	14	18	EGFR
O	18	19	,
O	20	24	HER2
O	24	25	,
O	26	29	and
O	30	34	HER3
O	35	44	signaling
O	45	49	with
B-intervention	50	57	AZD8931
I-intervention	58	60	in
I-intervention	61	72	combination
I-intervention	73	77	with
I-intervention	78	89	anastrozole
O	90	92	as
O	93	95	an
O	96	106	anticancer
O	107	115	approach
O	115	116	:
O	117	122	Phase
O	123	125	II
O	126	136	randomized
O	137	142	study
O	143	145	in
O	146	151	women
O	152	156	with
O	157	166	endocrine
O	166	167	-
O	167	174	therapy
O	174	175	-
O	175	177	na
O	177	178	Ã¯
O	178	180	ve
O	181	189	advanced
O	190	196	breast
O	197	203	cancer
O	203	204	.

O	205	212	AZD8931
O	213	215	is
O	216	218	an
O	219	225	orally
O	226	238	bioavailable
O	238	239	,
O	240	250	reversible
O	251	259	tyrosine
O	260	266	kinase
O	267	276	inhibitor
O	277	279	of
O	280	284	EGFR
O	284	285	,
O	286	290	HER2
O	290	291	,
O	292	295	and
O	296	300	HER3
O	301	310	signaling
O	310	311	.

O	312	315	The
O	316	321	Phase
O	322	324	II
O	325	329	MINT
O	330	335	study
O	336	337	(
O	337	351	ClinicalTrials
O	351	352	.
O	353	356	gov
O	357	368	NCT01151215
O	368	369	)
O	370	382	investigated
O	383	390	whether
O	391	397	adding
O	398	405	AZD8931
O	406	408	to
O	409	418	endocrine
O	419	426	therapy
O	427	432	would
O	433	438	delay
O	439	450	development
O	451	453	of
O	454	463	endocrine
O	464	474	resistance
O	475	477	in
O	478	486	patients
O	487	491	with
O	492	499	hormone
O	499	500	-
O	500	509	sensitive
O	510	518	advanced
O	519	525	breast
O	526	532	cancer
O	532	533	.

O	534	542	Patients
O	543	547	were
O	548	558	randomized
O	559	560	1
O	560	561	:
O	561	562	1
O	562	563	:
O	563	564	1
O	565	567	to
O	568	575	receive
O	576	581	daily
O	582	593	anastrozole
O	594	595	(
O	595	596	1
O	597	599	mg
O	599	600	)
O	601	603	in
O	604	615	combination
O	616	620	with
O	621	628	AZD8931
O	629	631	20
O	632	634	mg
O	635	640	twice
O	641	646	daily
O	647	648	(
O	648	651	bid
O	651	652	)
O	652	653	,
O	654	661	AZD8931
O	662	664	40
O	665	667	mg
O	668	671	bid
O	671	672	,
O	673	675	or
B-control	676	683	placebo
O	683	684	.

O	685	688	The
O	689	696	primary
O	697	706	objective
O	707	710	was
B-outcome-Measure	711	721	evaluation
I-outcome-Measure	722	724	of
I-outcome-Measure	725	736	progression
I-outcome-Measure	736	737	-
I-outcome-Measure	737	741	free
I-outcome-Measure	742	750	survival
I-outcome-Measure	751	752	(
I-outcome-Measure	752	755	PFS
I-outcome-Measure	755	756	)
O	757	759	in
O	760	768	patients
O	769	776	treated
O	777	781	with
O	782	793	combination
O	794	801	AZD8931
O	802	805	and
O	806	817	anastrozole
O	818	824	versus
O	825	836	anastrozole
O	837	842	alone
O	842	843	.

O	844	853	Secondary
O	854	864	objectives
O	865	873	included
B-outcome-Measure	874	884	assessment
I-outcome-Measure	885	887	of
I-outcome-Measure	888	894	safety
I-outcome-Measure	895	898	and
I-outcome-Measure	899	911	tolerability
O	911	912	,
B-outcome-Measure	913	922	objective
I-outcome-Measure	923	931	response
I-outcome-Measure	932	936	rate
O	936	937	,
O	938	941	and
B-outcome-Measure	942	949	overall
I-outcome-Measure	950	958	survival
O	958	959	.

O	960	962	At
O	963	966	the
O	967	974	interim
O	975	983	analysis
O	983	984	,
B-total-participants	985	988	359
O	989	997	patients
O	998	1002	were
O	1003	1013	randomized
O	1014	1017	and
O	1018	1026	received
O	1027	1038	anastrozole
O	1039	1041	in
O	1042	1053	combination
O	1054	1058	with
O	1059	1066	AZD8931
O	1067	1069	20
O	1070	1072	mg
O	1073	1074	(
O	1074	1075	n
O	1076	1077	=
B-intervention-participants	1078	1081	118
O	1081	1082	)
O	1082	1083	,
O	1084	1086	40
O	1087	1089	mg
O	1090	1091	(
O	1091	1092	n
O	1093	1094	=
B-intervention-participants	1095	1098	120
O	1098	1099	)
O	1099	1100	,
O	1101	1103	or
B-control	1104	1111	placebo
O	1112	1113	(
O	1113	1114	n
O	1115	1116	=
B-control-participants	1117	1120	121
O	1120	1121	)
O	1121	1122	;
O	1123	1125	39
O	1126	1127	%
O	1128	1130	of
O	1131	1139	patients
O	1140	1141	(
O	1141	1142	n
O	1143	1144	=
O	1145	1148	141
O	1148	1149	)
O	1150	1153	had
O	1154	1155	a
B-outcome	1156	1167	progression
I-outcome	1168	1173	event
O	1173	1174	.

B-outcome	1175	1181	Median
I-outcome	1182	1185	PFS
O	1186	1187	(
O	1187	1189	HR
O	1189	1190	;
O	1191	1193	95
O	1194	1195	%
O	1196	1198	CI
O	1199	1201	vs
O	1202	1209	placebo
O	1209	1210	)
O	1211	1213	in
O	1214	1217	the
O	1218	1225	AZD8931
O	1226	1228	20
O	1228	1229	,
O	1230	1232	40
O	1233	1235	mg
O	1235	1236	,
O	1237	1240	and
O	1241	1248	placebo
O	1249	1253	arms
O	1254	1257	was
B-iv-cont-median	1258	1260	10
I-iv-cont-median	1260	1261	.
I-iv-cont-median	1261	1262	9
O	1263	1264	(
O	1264	1265	1
O	1265	1266	.
O	1266	1268	37
O	1268	1269	;
O	1270	1271	0
O	1271	1272	.
O	1272	1274	91
O	1274	1275	-
O	1275	1276	2
O	1276	1277	.
O	1277	1279	06
O	1279	1280	,
O	1281	1282	P
O	1283	1284	=
O	1285	1286	0
O	1286	1287	.
O	1287	1290	135
O	1290	1291	)
O	1291	1292	,
B-iv-cont-median	1293	1295	13
I-iv-cont-median	1295	1296	.
I-iv-cont-median	1296	1297	8
O	1298	1299	(
O	1299	1300	1
O	1300	1301	.
O	1301	1303	16
O	1303	1304	;
O	1305	1306	0
O	1306	1307	.
O	1307	1309	77
O	1309	1310	-
O	1310	1311	1
O	1311	1312	.
O	1312	1314	75
O	1314	1315	,
O	1316	1317	P
O	1318	1319	=
O	1320	1321	0
O	1321	1322	.
O	1322	1325	485
O	1325	1326	)
O	1326	1327	,
O	1328	1331	and
B-cv-cont-median	1332	1334	14
I-cv-cont-median	1334	1335	.
I-cv-cont-median	1335	1336	0
I-cv-cont-median	1337	1343	months
O	1343	1344	,
O	1345	1357	respectively
O	1357	1358	.

O	1359	1361	No
O	1362	1372	indication
O	1373	1375	of
O	1376	1384	clinical
O	1385	1392	benefit
O	1393	1396	was
O	1397	1405	observed
O	1406	1415	following
O	1416	1425	treatment
O	1426	1430	with
O	1431	1438	AZD8931
O	1439	1442	for
O	1443	1446	the
O	1447	1456	secondary
O	1457	1466	endpoints
O	1466	1467	.

O	1468	1474	Safety
O	1475	1483	findings
O	1484	1490	showed
O	1491	1492	a
O	1493	1500	greater
B-outcome	1501	1510	incidence
I-outcome	1511	1513	of
I-outcome	1514	1522	diarrhea
O	1523	1524	(
B-iv-bin-percent	1524	1526	40
O	1526	1527	,
B-iv-bin-percent	1528	1530	51
O	1530	1531	,
O	1532	1535	and
B-cv-bin-percent	1536	1538	12
I-cv-bin-percent	1539	1540	%
O	1541	1544	for
O	1545	1552	AZD8931
O	1553	1555	20
O	1555	1556	,
O	1557	1559	40
O	1560	1562	mg
O	1562	1563	,
O	1564	1567	and
O	1568	1575	placebo
O	1575	1576	,
O	1577	1589	respectively
O	1589	1590	)
O	1590	1591	,
B-outcome	1592	1596	rash
O	1597	1598	(
B-iv-bin-percent	1598	1600	32
O	1600	1601	,
B-iv-bin-percent	1602	1604	48
O	1604	1605	,
O	1606	1609	and
B-cv-bin-percent	1610	1612	12
I-cv-bin-percent	1613	1614	%
O	1614	1615	)
O	1615	1616	,
B-outcome	1617	1620	dry
I-outcome	1621	1625	skin
O	1626	1627	(
B-iv-bin-percent	1627	1629	19
O	1629	1630	,
B-iv-bin-percent	1631	1633	25
O	1633	1634	,
O	1635	1638	and
B-cv-bin-percent	1639	1640	2
I-cv-bin-percent	1641	1642	%
O	1642	1643	)
O	1643	1644	,
O	1645	1648	and
B-outcome	1649	1658	acneiform
I-outcome	1659	1669	dermatitis
O	1670	1671	(
B-iv-bin-percent	1671	1673	16
O	1673	1674	,
B-iv-bin-percent	1675	1677	28
O	1677	1678	,
O	1679	1682	and
B-cv-bin-percent	1683	1684	2
I-cv-bin-percent	1685	1686	%
O	1686	1687	)
O	1688	1690	in
O	1691	1699	patients
O	1700	1707	treated
O	1708	1712	with
O	1713	1720	AZD8931
O	1721	1727	versus
O	1728	1735	placebo
O	1735	1736	.

O	1737	1744	AZD8931
O	1744	1745	,
O	1746	1748	in
O	1749	1760	combination
O	1761	1765	with
O	1766	1775	endocrine
O	1776	1783	therapy
O	1783	1784	,
O	1785	1789	does
O	1790	1793	not
O	1794	1800	appear
O	1801	1803	to
O	1804	1811	enhance
O	1812	1821	endocrine
O	1822	1836	responsiveness
O	1837	1840	and
O	1841	1843	is
O	1844	1854	associated
O	1855	1859	with
O	1860	1867	greater
O	1868	1872	skin
O	1873	1876	and
O	1877	1893	gastrointestinal
O	1894	1902	toxicity
O	1902	1903	.
